Cannabis Science Inc (OTCMKTS:CBIS) Gets Juiced on CBD News

Cannabis Science Inc (OTCMKTS:CBIS) Gets Juiced on CBD News


Cannabis Science Inc (OTCMKTS:CBIS) took a healthy jump up 13% today. CBIS was boosted on news that hit the wire today that it was close completing its new CBD formulation for treating Asthma and COPD (Chronic Obstructive Pulmonary Disease). CBIS has been on a downward slope YTD but the stock has rallied at the end of the year – up a total of 12% since the start of September.

This is an immense market segment, with approximately 5 million people with diagnosed cases of COPD in the United States alone and the 20 % prevalence of the Asthma, COPD Overlap Syndrome offers a known market of approximately 5 million doses per month potential for CBIS’ new formula.

Cannabis Science Inc (OTCMKTS:CBIS) defines itself according to the narrative of a leading-edge researcher and designer of cannabinoid solutions to health problems.

CBIS is involved in developing medicines for autism, blood pressure, cancer and cancer side effects, as well as for other illnesses comprising for general health maintenance. It also develops CS-TATI-1 for newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of available therapies; CS-S/BCC-1 to treat basal and squamous cell carcinomas; and a proprietary cannabis-based therapy for neurological conditions.

In addition, CBIS offers an online video-based medical cannabis education system, including courses, such as medical cannabis law, medical marijuana, cooking, horticulture, and bud tending; and manufactures and distributes specialty horse and pet grooming and topical applications. It has a license agreement with Apothecary Genetics Investments LLC to produce various brand formulations for California medical cannabis market.

Find out when $CBIS reaches critical levels. Subscribe to Right Now by entering your Email in the box below.

“Our recent development of our MDI and Rescue Inhaler medications for these patients in part is the reason this research evolved to treat this under-diagnosed syndrome. While our formulations for these medications achieve the desired effects for the illness targeted as a rescue medication they cannot treat effectively the diagnosis of the Overlap Syndrome. More interesting is the prevalence of ACOS observed among populations of patients diagnosed with COPD.

Our new formulary will target four aspects of this illness inflammation, airway constriction, capacity, and anxiety. Cannabinoid extracts have many unique properties as well as an inflammatory agent these extracts also do aid in controlling anxiety and it is our belief lung capacity. The strain we are working with is one that has lung expansion properties, this certain strain chemical makeup causes the lungs to expand or hyper-inflate once the dose has been administered and over a subscribed to therapy term is expected to build back lung muscle strength in the weakened lungs along with increased volume capacity as the lungs are stressed much like breathing exercises would do for the patient that no longer has the ability to effectively do deep breathing exercises,” stated Chief Medical Officer: Dr. Allen Herman.

This news has gotten investors attention today as CBD oil research is a very lucrative subset of the cannabis sector. CBIS is looking for test subjects currently and the company will next be looking at the oxygen level for subjects along with Asthma flare-ups. Those results will really steer CBIS in the upcoming year.

Currently holding at a market capitalization of $139.92M, CBIS is fighting back against the bear but is not out of the woods yet. CBD oils are a very unique sector and stand to be quite lucrative if a breakout happens here. We will be updating readers as more info colors out for CBIS. Sign-up for continuing coverage on shares of $CBIS stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in $CBIS, either long or short, and we have not been compensated for this article.

Sign Up for our 100% FREE Oracle Dispatch Newsletter